Long-term safety study of ALXN2220 in adults with transthyretin amyloid cardiomyopathy
This study is an extension of a previous trial (study 301) for adults with a heart condition called transthyretin amyloid cardiomyopathy. It aims to evaluate the long-term safety and effectiveness of an investigational drug (ALXN2220). Participants who completed the earlier study without stopping the drug or withdrawing consent may be eligible to continue receiving the treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed the blinded treatment period of the previous study (study 301).
- You must not have permanently stopped the study drug or withdrawn consent during study 301.
- You must not have a known allergy to the study drug or its components.
- You must not have had a heart transplant or permanent heart device (e.g., left ventricular assist device).
- You must not have any medical condition that, in the doctor's judgment, could put you at risk or interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called Coramitug for people with heart failure due to ATTR amyloidosis, a condition where abnormal proteins build up in the heart. The study aims to see if Coramitug can improve heart function and quality of life.
This study follows people with a heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM) who are starting treatment with acoramidis. It aims to see how well the medicine works in everyday medical practice.
This study follows patients with ATTR amyloidosis over time to understand how the disease affects them. It does not test a new treatment—instead, it asks you to fill out questionnaires about your health and symptoms to help doctors learn more about the condition.
This trial tests a new drug called ALXN1920 for adults with primary membranous nephropathy (PMN), a kidney disease where the immune system attacks the kidneys. It is for people at high risk of their disease getting worse, and it compares the new drug added to standard care versus standard care alone.
This study looks at the long-term safety of the study drug acoramidis for people living with a heart condition called ATTR-CM. It may help doctors understand the long-term effects and benefits of this treatment.
This study tests a new treatment, NTLA-2001, for people with a type of heart disease called transthyretin amyloidosis with cardiomyopathy. It aims to see if the medicine can help improve heart function and quality of life.
Hear when a new Transthyretin Amyloid Cardiomyopathy (ATTR-CM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.